Voyager Therapeutics (FRA:VT6) Insider Ownership: 0.00 % (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VT6 Voyager Therapeutics Inc FRA:VT6
54 GF Score
Price €2.59
GF Value €1.38
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics Insider Ownership?

Voyager Therapeutics FRA:VT6 +1.01% 54 Insider Ownership is 0.00 % as of Aug. 08, 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 54/100 and a GF Value™ of €1.38 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Voyager Therapeutics's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Voyager Therapeutics's Institutional Ownership is 24.31%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Voyager Therapeutics's Float Percentage Of Total Shares Outstanding is 85.17%.

Voyager Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Insider Ownership Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Voyager Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:VT6
54GF Score
Voyager Therapeutics Inc FRA:VT6
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Voyager Therapeutics (FRA:VT6) has a Insider Ownership of 0.00 % as of Aug. 08, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Insider Ownership too high?
Voyager Therapeutics' current Insider Ownership is 0.00 %. Overall, Voyager Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Insider Ownership compare to NERV and DTIL?
Voyager Therapeutics' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.38, compared to a current price of €2.59 — trading 87.5% above its estimated fair value. The current Insider Ownership is 0.00 %. Voyager Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Insider Ownership is 0.00 % as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €2.59 is trading 87.5% above its estimated GF Value™ of €1.38. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Insider Ownership: 0.00 %
  • GF Value™: €1.38 vs. price of €2.59 (87.5% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
54GF Score

Get the complete analysis for FRA:VT6

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.59
Price
€1.38
GF Value